The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

被引:24
作者
Kim, Moon H. [1 ]
Tsuhako, Amy Lew [1 ]
Co, Erick W. [1 ]
Aftab, Dana T. [1 ]
Bentzien, Frauke [1 ]
Chen, Jason [1 ]
Cheng, Wei [1 ]
Engst, Stefan [1 ]
Goon, Levina [1 ]
Klein, Rhett R. [1 ]
Le, Donna T. [1 ]
Mac, Morrison [1 ]
Parks, Jason J. [1 ]
Qian, Fawn [1 ]
Rodriquez, Monica [1 ]
Stout, Thomas J. [1 ]
Till, Jeffrey H. [1 ]
Won, Kwang-Ai [1 ]
Wu, Xiang [1 ]
Yakes, F. Michael [1 ]
Yu, Peiwen [1 ]
Zhang, Wentao [1 ]
Zhao, Yeping [1 ]
Lamb, Peter [1 ]
Nuss, John M. [1 ]
Xu, Wei [1 ]
机构
[1] Exelixis, San Francisco, CA 94080 USA
关键词
Receptor tyrosine kinase; Angiogenesis; KDR; VEGFR; Flt; FGFR; PDGFR; Oxindole; Indolin-2-one; GROWTH-FACTOR RECEPTOR; VEGF; ANTIANGIOGENESIS; INDOLIN-2-ONES; IDENTIFICATION; RESISTANCE; AG-013736; AGENT;
D O I
10.1016/j.bmcl.2012.06.029
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4979 / 4985
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 2012, Pharmacol. Pharm, DOI DOI 10.4236/PP.2012.31010
[2]   Targeted treatments in colorectal cancer: state of the art and future perspectives [J].
Arnold, Dirk ;
Seufferlein, Thomas .
GUT, 2010, 59 (06) :838-858
[3]  
Bannen L. C., 2004, [No title captured], Patent No. [WO 2004050681 A2, 2004050681]
[4]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[5]   Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].
Casanovas, O ;
Hicklin, DJ ;
Bergers, G ;
Hanahan, D .
CANCER CELL, 2005, 8 (04) :299-309
[6]   FDA drug approval summary:: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer [J].
Cohen, Martin H. ;
Gootenberg, Joe ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2007, 12 (06) :713-718
[7]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[8]   Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms [J].
Erber, R ;
Thurnher, A ;
Katsen, AD ;
Groth, G ;
Kerger, H ;
Hammes, HP ;
Menger, MD ;
Ullrich, A ;
Vajkoczy, P .
FASEB JOURNAL, 2003, 17 (15) :338-340
[9]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335
[10]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676